Insmed (INSM)
NASDAQ:INSM
Want to see INSM full AI Analyst Report?
INSM Stock Chart & Stats
$144.48
-$1.02(-1.54%)
At close: 4:00 PM EST
$144.48
-$1.02(-1.54%)
Day’s Range― - ―
52-Week Range$90.39 - $212.75
Previous CloseN/A
Volume462.72K
Average Volume (3M)4.34M
Market Cap
$21.21B
Enterprise Value$20.87B
Total Cash (Recent Filing)$1.22B
Total Debt (Recent Filing)$748.43M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Jul 30, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.75
Shares Outstanding216,752,460
10 Day Avg. Volume4,285,849
30 Day Avg. Volume4,340,977
Financial Highlights & Ratios
PEG Ratio-1.93
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue25.47
Enterprise Value/Gross Profit31.22
Enterprise Value/Ebitda-19.30
Forecast
1Y Price Target
$200.44Price Target Upside38.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.82
Revenue Forecast (FY)$1.69B
Bulls Say, Bears Say
Bulls Say
BRINSUPRI Commercial RampSustained rapid BRINSUPRI uptake and a reiterated $1B+ guidance indicate durable commercial traction. Expanding prescriber adoption and sequential revenue build create a predictable revenue ramp that can materially fund operating needs, support margin expansion, and underpin the stated path to cash-flow positivity in 2027.
Reimbursement And Patient Support StrengthHigh payer approval rates and fast authorizations materially reduce reimbursement friction and time-to-treatment. Coupled with >80% patient support enrollment and improved refill cadence, this builds durable adherence and retention advantages, improving lifetime revenue predictability and lowering long-term acquisition and churn risks.
Improved Balance Sheet And Cash RunwayMarkedly lower debt, positive equity and about $1.2B in cash provide financial flexibility to fund launches, pivotal Phase III programs and operating losses. Low leverage reduces near-term refinancing/dilution risk and affords time to execute the commercial ramp and reach the targeted cash-flow positivity without immediate capital raises.
Bears Say
High Cash BurnVery large negative operating and free cash flow show the business still consumes substantial cash to support commercial rollout and R&D. Persistent high burn makes the company contingent on continued strong revenue execution and disciplined spending; failure to hit ramp targets could force external financing or program delays.
Large Operating Losses Vs. RevenueDespite healthy gross margins, operating losses and deeply negative net margins reflect a structural expense base with elevated R&D and SG&A vs. current revenue. Until operating costs scale down relative to top-line growth, sustainable profitability and return on invested capital will remain challenged, limiting long-term financial resilience.
Pipeline Narrowing And Commercialization RiskTerminating brensocatib narrows therapeutic diversification and heightens reliance on BRINSUPRI/ARIKAYCE and TPIP programs. Combined with MFN-driven European launch pauses and competitor treprostinil programs, this raises execution and concentration risk: weaker BRINSUPRI uptake or trial setbacks would more sharply impact growth and cash generation.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $90.39 and its highest was $212.75 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $21.21B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Jul 30, 2026 which is in 43 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on May 07, 2026. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.963 by $0.203.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.75.
How many shares outstanding does Insmed have?
Insmed has 216,752,460 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.963. Following the earnings report the stock price went down -23.408%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$200.44 (38.74% Upside)
$200.44 (38.74% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 749.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.28%
12-Months-Change
Fundamentals
Return on Equity
-130.11%
Trailing 12-Months
Asset Growth
15.15%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
INSM Company Deck
INSM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong commercial and clinical achievements: notably the BRINSUPRI launch with 44% sequential growth, high payer approvals (~90%), strong patient support enrollment (>80%), improved refill/continuation metrics, positive ARIKAYCE Phase IIIb ENCORE results suggesting a substantially larger addressable market, and ongoing TPIP Phase III progress. Financially the company has a solid cash position (~$1.2B) and reiterated guidance, with an expected path to cash flow positivity in 2027. Offsetting items include the completion of the early 'ready-and-waiting' demand tail (requiring organic uptake going forward), international launch uncertainty due to MFN, potential future payer policy tightening, higher near-term operating spend, and some ambiguity around discontinuation drivers. Overall, the positives—particularly the standout launch metrics, clinical wins, and balance sheet strength—appear to outweigh the risks and uncertainties discussed on the call.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$200.44
▲(38.74% Upside)
Technical Analysis
Ownership Overview
0.72% Insiders
30.05% Mutual Funds
34.60% Other Institutional Investors
14.94% Public Companies and
Individual Investors